Peter Kakavas, MD
Cardiovascular Disease · Palos Park, ILNPI 1528022191
Payments from drug & device makers
Across 364 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$967
- E.r. Squibb & Sons, L.L.C.$957
- Novartis$742
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$420
- Kestra Medical Technology Services, Inc.$398
- Esperion Therapeutics, Inc.$283
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,659100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 76 | $967 |
| E.r. Squibb & Sons, L.L.C. | 84 | $957 |
| Novartis | 46 | $742 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 30 | $420 |
| Kestra Medical Technology Services, Inc. | 4 | $398 |
| Esperion Therapeutics, Inc. | 14 | $283 |
| AstraZeneca | 20 | $281 |
| Johnson & Johnson | 19 | $280 |
| Novo Nordisk | 9 | $223 |
| Amgen | 11 | $182 |
| Boehringer Ingelheim | 5 | $104 |
| Scpharmaceuticals Inc. | 5 | $100 |
| Alnylam Pharmaceuticals Inc. | 4 | $98 |
| Medtronic | 3 | $60 |
| Sanofi-aventis U.S. LLC | 4 | $58 |
| Boston Scientific | 1 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| Abbott | 2 | $45 |
| Akcea Therapeutics, Inc. | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 3 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| Preventice Services, LLC | 2 | $31 |
| Bardy Diagnostics, Inc. | 2 | $30 |
| Merck | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $28 |
| Heartflow, Inc. | 1 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Edwards Lifesciences | 1 | $19 |
| Mannkind Corporation | 1 | $18 |
| Portola Pharmaceuticals, LLC | 1 | $16 |
| Chiesi USA, Inc. | 1 | $16 |
| Sandoz | 1 | $15 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Assure WCD$332
How this compares
$5,682 in reported general payments places this provider in the 70th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 218 | $277,983 |
| EntrestoSacubitril/Valsartan | 52 | $81,290 |
| XareltoRivaroxaban | 37 | $47,547 |
| Repatha SureclickEvolocumab | 11 | $16,196 |
| Atorvastatin Calcium | 539 | $6,506 |
| Ezetimibe | 167 | $4,301 |
| Metoprolol Succinate | 232 | $3,884 |
| Metoprolol Tartrate | 241 | $2,279 |
| Olmesartan Medoxomil | 105 | $2,166 |
| Rosuvastatin Calcium | 155 | $2,079 |
| Losartan Potassium | 152 | $1,862 |
| Valsartan | 56 | $1,539 |
| Amlodipine Besylate | 174 | $1,513 |
| Furosemide | 204 | $1,454 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 37 | $1,415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $967 | $277,983218 claims |
| NovartisEntresto | $742 | $81,29052 claims |
| Johnson & JohnsonXarelto | $280 | $47,54737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Palos Park
- Noel CambaPalos Park$130K
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Lokesh ChandraHazel Crest$2.7M
- Steven LupovitchArlington Heights$2.6M
- Nitasha SarswatChicago$2M
- Alan BrownNaperville$1.5M
- Alexander AdlerPeoria$1.5M
- Clifford KavinskyMaywood$1.4M
- Sanjiv ShahChicago$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.